Sunday, June 1, 2025
6/1/2025
Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy - Abstract The use of T cells engineered to express specific chimeric antigen receptors (CARs) to treat cancer has generated durable cures for many types of cancer and resulted in the first FDA approved CAR-T cell therapy to treat childhood acute lymphoblastic leukemia in 2017. Despite this success, CAR-T immunotherapies have been much less effective at targeting solid tumors. Part of this limited success stems from the solid tumor microenvironment, which forms a physical barrier to immune cell infiltration and produces soluble factors that downregulate T cell activity and accelerate T cell exhaustion. While immunotherapies targeting solid tumors are initially effective, the tumor microenvironment’s inhibition of T cells prevents these treatments from producing durable responses. In this application, we propose a novel CAR-T cell therapy aimed to improve outcomes for patients with advanced stage pancreatic cancer by overcoming the deficiencies that plague current CAR-T cell therapies. To this end, we will engineer T cells to express multiple CARs, enabling these cells to target tumor cells and cells in the immune-suppressive tumor microenvironment. Specifically, we will leverage the non-viral, Tc Buster DNA transposon system to insert a large multicistronic genetic construct containing multiple CARs and a selection marker into T cells. Using this platform, we will generate T cells with CARs targeting mesothelin (MSLN), a protein expressed by 80-85% of pancreatic cancer tumors, and fibroblast activation protein (FAP), a marker of cancer associated fibroblasts in the tumor microenvironment. We will then select a pure population of T cells expressing MSLN- and FAP-CARs and determine the activity and specificity of these cells in vitro. We expect that engineered T cells will generate a specific and robust response, eliciting cytotoxic functions only against cells expressing their target antigen. We will then determine the efficacy of engineered T cells in vivo using a xenograft mouse model to generate MSLN and FAP positive pancreatic carcinomas followed by adoptive transfer of T cells. We expect immunotherapeutic delivery of bispecific T cells expressing FAP-CARs and MSLN- CARs will elicit a robust and long-lasting T cell response against MSLN+/FAP+ solid tumors resulting in tumor shrinkage and increased survival. Furthermore, we expect the development of a flexible, efficient, and reliable process to generate bispecific T cells with a single, non-viral gene delivery approach will facilitate the emergence of novel therapies to overcome many issues facing engineered T cell therapy today, including antigen escape and target specificity.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).